Humana targets 3% Medicare Advantage margin by 2028 as turnaround takes shape

Humana set a 3% Medicare Advantage margin target by 2028 while pursuing 25% membership growth in 2026, betting it can rebuild profitability without sacrificing market share in a sector where competitors are scaling back benefits to protect margins.

"The turnaround is no longer about growing membership — it's about rebuilding profitability through disciplined pricing, stronger product design and better retention," Humana said in its strategic update, reaffirming 2026 adjusted EPS guidance of at least $9.00.

The company is working to improve medical cost trends through tighter care management and stronger operational execution. It is also investing to rebuild its Medicare Star Ratings, a key driver of future reimbursement from the Centers for Medicare and Medicaid Services. Higher ratings would increase quality bonus payments, strengthen its competitive position and support long-term profitability. The medical loss ratio — the share of premium dollars spent on medical claims — is a key metric investors will watch as Humana balances growth with cost discipline.

The 3% margin target is thin relative to the broader managed care industry, where large diversified insurers typically target 4% to 5% margins in their Medicare businesses. The simultaneous pursuit of 25% membership growth could pressure near-term profitability, as new members often have higher initial medical costs. Delivering on cost controls and Star Ratings improvements will determine whether Humana can translate its strategy into sustainable earnings recovery by 2028.

How Peers Are Navigating the Same Challenge

Restoring Medicare Advantage profitability has become a priority across the health insurance industry. UnitedHealth Group is emphasizing disciplined pricing, stronger care management and value-based care to improve margins, prioritizing sustainable profitability over aggressive growth. CVS Health is repricing Medicare Advantage plans, refining benefits and strengthening medical cost management to rebuild margins after its Aetna unit faced elevated medical costs.

Unlike many competitors that have scaled back benefits, Humana continues to expect approximately 25% growth in individual Medicare Advantage membership in 2026. The focus is on attracting higher-quality members through disciplined pricing and stronger product design rather than pursuing growth at any cost. This approach carries execution risk — if the company misprices its plans or fails to retain the right members, the margin target could slip.

Stock Performance and Valuation

Shares of Humana have gained 53.1% year to date, outperforming the broader industry's 28.5% growth. The rally reflects investor optimism about the turnaround plan, though the 3% margin target remains a key test. The company's ability to control medical costs and improve Star Ratings will be critical to sustaining that momentum.

Despite elevated healthcare utilization and a challenging regulatory environment, Humana reaffirmed its 2026 adjusted EPS guidance of at least $9.00, reflecting confidence in its turnaround plan despite the temporary Star Ratings headwind. The near-term focus is on controlling medical costs, improving Star Ratings and turning membership growth into higher profits.

What's at Stake

The 3% Medicare Advantage margin target represents one of the most important milestones for Humana's long-term earnings recovery. If achieved by 2028, it would signal that the company has successfully navigated the industry's margin pressures and regulatory headwinds. If not, the stock's year-to-date gains could reverse as investors reassess the viability of the turnaround.

The last time Humana faced a similar margin compression cycle was in 2018-2019, when the company's Medicare Advantage margins fell below 2% before recovering through pricing adjustments and cost initiatives. That recovery took roughly two years. The current plan gives the company until 2028 — a longer runway, but with the added complexity of Star Ratings headwinds and elevated industry-wide utilization.

This article is for informational purposes only and does not constitute investment advice.